Skip to content
Open access

Roles of LTF and HAMP in Neuronal Ferroptosis in Alzheimer's Disease Cell Model

Aug 2026 · Theoretical and Natural Science · Vol 187, pp. 7-21 · 0 citations

TL;DR

Bioinformatics analysis of hippocampal RNA-sequencing data from AD patients and healthy controls revealed LTF and HAMP as key DEGs related to iron homeostasis, potentially linked to ferroptosis in AD.

Abstract

Dysregulation of iron homeostasis and ferroptosis is increasingly implicated in Alzheimer's disease (AD) pathology. Lactotransferrin (LTF) and hepcidin (HAMP) are key regulators of neuronal iron metabolism, but their role in AD-related ferroptosis remains unclear. Bioinformatics analysis of hippocampal RNA-sequencing data from AD patients and healthy controls identified differentially expressed genes (DEGs) associated with iron metabolism. SH-SY5Y cells were treated with Aβ oligomers to establish AD cell models and further subjected to siRNA-mediated knockdown of LTF or HAMP. Ferroptosis was evaluated using Fe²⁺ accumulation, lipid reactive oxygen species (ROS), mitochondrial morphology, MDA/GSH levels, and the expression of core ferroptosis regulators (GPX4, SLC7A11, ACSL4). Cell viability, LDH release, and apoptosis were also assessed. Bioinformatics analysis revealed LTF and HAMP as key DEGs related to iron homeostasis, potentially linked to ferroptosis in AD. In vitro, Aβ treatment decreased LTF and HAMP expression, induced Fe²⁺ accumulation, oxidative stress, mitochondrial damage, and ferroptotic cell death. Knockdown of LTF or HAMP further exacerbated these effects, while treatment with the ferroptosis inhibitor Fer-1 partially restored cellular homeostasis and viability. The data suggest a regulatory role of LTF and HAMP in neuronal ferroptosis. Notably, hyper-expression of LTF and HAMP observed in post-mortem AD hippocampal samples likely reflects compensatory negative feedback mechanisms in late-stage disease. LTF and HAMP act as protective modulators against neuronal ferroptosis in AD. Their early downregulation promotes iron overload and oxidative stress, whereas compensatory upregulation in vivo delays ferroptosis. Targeting LTF and HAMP-mediated pathways may provide novel therapeutic strategies for mitigating AD progression.

Read PDF

Similar papers

Review Sep 2026

Ferroptosis in Neurodegenerative Diseases: Iron Dysregulation, GPX4/FSP1 Signaling, and Emerging Neuroprotective Strategies.

INTRODUCTION Neurodegenerative Diseases (NDDs), including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Multiple Sclerosis (MS), are increasingly associated with ferroptosis, a regulated irondependent form of cell death characterised by the exces...

Nainsi Kumari, Shruti Dwivedi, Satyam Yadav et al. · 0 citations
Review Aug 2026

Ferroptosis and Alzheimer's disease: Neuroimmune crosstalk and pharmacological opportunities.

Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue, which restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.

Yelizaveta A. Marakhovskaya, A. Churov, Mikhail Arbatsky et al. · 0 citations
Open access Sep 2026

β-Amyloid and Glutathione Dysregulation Cooperatively Drive Lipid Peroxidation and Ferroptosis in Neuron-Like Cells.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) accumulation and oxidative stress, with aging being its greatest risk factor. Age-related glutathione (GSH) depletion may increase neuronal vulnerability to Aβ toxicity, but the underlying mechanisms remain unclear. Her...

Kazi Rafsan Radeen, Cai-Li Hao, Zong-Bo Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.